Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials  by Fonseca, Vivian A. et al.
Journal of Diabetes and Its Complications 28 (2014) 399–405
Contents lists available at ScienceDirect
Journal of Diabetes and Its Complications
j ourna l homepage: WWW.JDCJOURNAL.COMReductions in systolic blood pressure with liraglutide in patients with type 2
diabetes: Insights from a patient-level pooled analysis of six randomized
clinical trials☆
Vivian A. Fonseca a,⁎, J. Hans DeVries b, Robert R. Henry c, Morten Donsmark d,
Henrik F. Thomsen e, Jorge Plutzky f
a Tulane University, New Orleans, LA, USA
b Academic Medical Centre, University of Amsterdam, Netherlands
c University of California San Diego and VA San Diego Healthcare System, San Diego, CA, USA
d Novo Nordisk A/S, Soeborg, Denmark
e Novo Nordisk A/S, Aalborg Øst, Denmark
f Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USAConﬂicts of interest: V.F. has received advisory b
bureau honoraria from Novo Nordisk, and his institution
from NovoNordisk; V.F. is currently Editor-in-Chief of this
has received advisory board honoraria and speakers’
Nordisk, and his institution has received research fund
institution has received research funding from Nov
consultancy fees from Novo Nordisk. M.D. and H.T. ar
own shares in Novo Nordisk A/S. These analyses were sp
Copenhagen, Denmark. All authors discussed the dat
important intellectual content, and approved the versi
out the statistical analyses.
☆ Clinical trial registration: This patient-level pooled
the following six clinical trials, registered at Clini
NCT00318461, NCT00294723, NCT00333151, NCT00331
⁎ Corresponding author at: Departments of Medici
University Health Sciences Center, 1430 Tulane Avenue,
USA. Tel.: +1 504 585 4026; fax: +1 504 988 6271.
E-mail address: vfonseca@tulane.edu (V.A. Fonseca)
1056-8727©2014TheAuthors.PublishedbyElsevier Inc.
http://dx.doi.org/10.1016/j.jdiacomp.2014.01.009
Opa b s t r a c ta r t i c l e i n f oArticle history:
Received 15 August 2013
Received in revised form 6 December 2013
Accepted 12 January 2014
Available online 21 January 2014
Keywords:
Type 2 diabetes
Hypertension
Blood pressure
Liraglutide
Aims: To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2
diabetes (T2D), and assess the inﬂuence of covariates on observed SBP reductions.
Methods: A patient-level pooled analysis of six phase 3, randomized trials was conducted.
Results: The analysis included 2792 randomized patients. In the intention-to-treat population (n = 2783),
mean [±SE] SBP reductions from baseline with liraglutide 1.2 mg (2.7 [0.8] mmHg) and 1.8 mg (2.9 [0.7]
mmHg) once daily were signiﬁcantly greater than with placebo (0.5 [0.9] mmHg; P = 0.0029 and
P = 0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated
with signiﬁcantly greater SBP reductions than glimepiride and, at a dose of 1.8 mg, insulin glargine and
rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson’s correlation
coefﬁcient: 0.08–0.12; P ≤ 0.0148). No dependence of these reductions on concomitant antihypertensive
medications was detected (P = 0.1304). Liraglutide 1.2 and 1.8 mg were associated with mean increases
in pulse of 3 beats per minute (bpm), versus a 1 bpm increase with placebo (P b 0.0001 for each dose
versus placebo).
Conclusions: Liraglutide reduces SBP in patients with T2D, including those receiving concomitant
antihypertensive medication.
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Approximately 20%–60% of patients with type 1 or type 2 diabetes
have hypertension, varying as a function of obesity, ethnicity, and age
(Arauz-Pacheco, Parrott, & Raskin, 2003). Hypertension substantially
increases the risk of both microvascular and macrovascular diabetic
complications, including stroke, coronary artery disease, peripheral
vascular disease, retinopathy, nephropathy, and possibly neuropathy
(Adler, Stratton, Neil, et al., 2000; UK Prospective Diabetes Study
Group, 1998). In recent years, data from well-designed randomized
clinical trials have demonstrated the effectiveness of treating
hypertension, lipids, and glycemia in reducing vascular complications
of diabetes, albeit with varying beneﬁt (Gaede, Lund-Andersen,
Parving, & Pedersen, 2008; Holman, Paul, Bethel, Matthews, & Neil,
2008; Kearney, Blackwell, Collins, et al., 2008; Turnbull, Neal, Algert, 
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(BP) is one of the most effective strategies for improving long-term
cardiovascular (CV) outcomes for patients with diabetes (Arauz-
Pacheco et al., 2003).
The American Diabetes Association (ADA) and the Joint National
Committee on Prevention, Detection, Evaluation and Treatment of
High Blood Pressure recommend a target BP of b140/80 mmHg or
b130/80 mmHg for individuals with type 2 diabetes (American
Diabetes Association, 2013; Chobanian, Bakris, Black, et al., 2003;
Gaede et al., 2008). Meanwhile, the European Association for the
Study of Diabetes (EASD) recommend a BP target of b130/80 mmHg,
or b125/75 mmHg in those with renal impairment (Ryden, Standl,
Bartnik, et al., 2007). The latter recommendation is supported by the
American Association of Clinical Endocrinologists (AACE) Hyperten-
sion Task Force, who reasoned that the more stringent BP target of
b120/75 mmHg may be even more effective in slowing the progres-
sion of CV and renal complications, particularly in the presence of
proteinuria (Torre, Bloomgarden, Dickey, et al., 2006). Achieving this
BP target is challenging, often requiring multiple antihypertensive
medications, which can lead to problems with adherence, side effects,
and drug–drug interactions. Patients with type 2 diabetes often need
combination antidiabetic therapy to achieve appropriate glucose
control, which may have little or no effect on BP. Furthermore, these
individuals are frequently treated with multiple additional medica-
tions to treat dyslipidemia and prior CV events.
In addition to their well-appreciated effects to reduce hypergly-
cemia, glucagon-like peptide (GLP)-1 receptor agonists have effects
on the CV system, including BP lowering — perhaps due to associated
weight loss (Vilsbøll, Christensen, Junker, Knop, & Gluud, 2012),
natriuresis (Kim, Platt, Shibasaki, et al., 2013; Thomson, Kashkouli, &
Singh, 2013), vasodilation (Gaspari, Liu, Welungoda, et al., 2011; Kim
et al., 2013), or a combination of these mechanisms. While the
detection of GLP-1 receptors using immunological techniques is
technically challenging (Pyke & Knudsen, 2013), GLP-1 receptors have
been detected in human CV tissues using reverse transcription
polymerase chain reaction (RT-PCR) (Wei & Mojsov, 1995), and
GLP-1 receptors have been located to the myocardium (predomi-
nantly to the atria Kim et al., 2013), microvascular endothelium, and
coronary smooth muscle cells in mice (Ban et al., 2008; Kim et al.,
2013). Both direct and indirect effects of GLP-1 receptor agonists on
the CV system have been proposed (Ban et al., 2008; Gaspari et al.,
2011; Kim et al., 2013).
The ‘Liraglutide Effect and Action in Diabetes’ (LEAD) clinical
development program, comprising six randomized clinical trials,
evaluated the efﬁcacy and safety of the GLP-1 analogue liraglutide in
different type 2 diabetes populations: from drug-naïve patients to
those for whom single or multiple oral antidiabetic drugs (OADs) had
failed (Buse, Rosenstock, Sesti, et al., 2009; Garber, Henry, Ratner,
et al., 2009; Marre, Shaw, Brandle, et al., 2009; Nauck, Frid,
Hermansen, et al., 2009; Russell-Jones, Vaag, Schmitz, et al., 2009;
Zinman, Gerich, Buse, et al., 2009). Active comparators in these trials
included glimepiride, rosiglitazone, insulin glargine, and the GLP-1
receptor agonist exenatide. Across the LEAD trials, liraglutide
improved glycosylated hemoglobin (HbA1c) by 1.0%–1.5%, and was
associated with sustained body weight reductions of 2.0–3.4 kg (Buse
et al., 2009; Garber et al., 2009; Marre et al., 2009; Nauck et al., 2009;
Russell-Jones et al., 2009; Zinman et al., 2009). BP was a pre-speciﬁed
secondary endpoint in all six randomized LEAD trials. Although the
trials were not statistically powered to assess BP lowering, consistent
reductions in systolic BP (SBP)with liraglutide (1.8 mg or 1.2 mg once
daily) were observed, with reductions ranging from 2.1 to 6.7 mmHg
from baseline to the end of the treatment period under evaluation
(26–52 weeks) (Buse et al., 2009; Garber et al., 2009; Marre et al.,
2009; Nauck et al., 2009; Russell-Jones et al., 2009; Zinman et al.,
2009). Small, non-signiﬁcant reductions in diastolic BP from baseline
were observed with liraglutide in most of these trials (Buse et al.,2009; Garber et al., 2009; Marre et al., 2009; Nauck et al., 2009;
Russell-Jones et al., 2009; Zinman et al., 2009).
In this study, we used patient-level data to carry out a pooled
analysis of the effects of liraglutide versus comparators on SBP in a
large patient population (almost 2800 individuals) to gain more
deﬁnitive evidence of a change in SBP following treatment with
liraglutide, to quantify the change, and to investigate its determinants.
2. Materials and methods
2.1. Study design and patients
A database was compiled including 26-week clinical data from ﬁve
randomized controlled trials, LEAD-1, -2, -4, -5 and -6, and 28-week
clinical data from LEAD-3. These trials were sponsored by Novo
Nordisk A/S (Copenhagen, Denmark). Study designs, entry criteria,
and primary efﬁcacy and safety results have been published
previously for all six trials (Buse et al., 2009; Garber et al., 2009;
Marre et al., 2009; Nauck et al., 2009; Russell-Jones et al., 2009;
Zinman et al., 2009). All trials followed protocols approved by
institutional review boards or ethics committees, and were conducted
in accordance with the Declaration of Helsinki (World Medical
Association General Assembly, 2008).
Some heterogeneity of trial design was present. Four of the trials
were placebo-controlled (LEAD-1, -2, -4 and -5) (Marre et al., 2009;
Nauck et al., 2009; Russell-Jones et al., 2009; Zinman et al., 2009),
while the remaining two trials compared liraglutide with either
exenatide twice daily (LEAD-6) (Buse et al., 2009), or glimepiride
(LEAD-3) (Garber et al., 2009). While four of the trials were
completely double-blinded, one trial was open-label (LEAD-6) (Buse
et al., 2009) and the LEAD-5 study had an open-label arm (Russell-
Jones et al., 2009). Patients from two trials received liraglutide 1.8 mg
once daily (Buse et al., 2009; Russell-Jones et al., 2009); the remaining
four trials included liraglutide 1.2 and 1.8 mg once daily arms (Garber
et al., 2009; Marre et al., 2009; Nauck et al., 2009; Zinman et al., 2009).
Enrolled patients continued their baseline antihypertensive and
lipid-lowering therapies, as the protocols did not make any
recommendations to change these existing therapies. Patients
randomly assigned to the liraglutide groups received liraglutide
subcutaneously once daily. Liraglutide doses were escalated to the
target dose (1.2 or 1.8 mg) in weekly increments of 0.6 mg, from an
initial dose of 0.6 mg. Since the purpose of the analysis was to
evaluate the effects of approved maintenance doses of liraglutide (1.2
and 1.8 mg once daily) (Victoza (Liraglutide) Summary of Product
Characteristics, 2012; Victoza (liraglutide) (liraglutide), 2013), pa-
tients randomized to a ﬁnal dose of liraglutide 0.6 mg were not
included in this analysis.
2.2. BP and pulse measurements
BP was measured according to American Heart Association
(AHA) recommendations using a standardized auscultatory method
(Pickering, Hall, Appel, et al., 2005). Patients were instructed to avoid
caffeine, smoking and exercise ≥30 min before BP measurement, and
were sitting for ≥5 min prior to the ﬁrst reading. Mercury
sphygmomanometers were used, with the use of aneroid or hybrid
sphygmomanometers restricted to circumstances where mercury
devices were banned due to environmental concerns. The size of the
cuff was selected so that the bladder of the cuff encircled at least 80%
of the arm circumference, and the width of the cuff was at least 40% of
the arm circumference. The measurements were taken with precision
to the nearest 2 mmHg. BP was checked on both arms at the ﬁrst visit:
in case of an inter-arm difference, the arm with the higher reading
was used for all subsequent measurements. At least two measure-
ments at intervals of at least 2 min were performed at baseline and
follow-up visits. In the event of a N5 mmHg difference between the
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obtained. The average of these readings was used to represent the
patient’s BP. Resting pulse data were also captured.
2.3. Statistical methods
Baseline data, 26-week data from LEAD-1, -2, -4, -5 and -6, and 28-
week data from LEAD-3 were collected and analyzed. Missing post-
baseline data were imputed using the last observation carried forward
(LOCF) method for all studies. Changes in SBP and pulse from baseline
were compared between treatment groups using a linear mixed effect
model that included treatment, trial, and previous OAD treatment as
ﬁxed effects, baseline value of the dependent variable as a covariate,
country as a random effect and trial-speciﬁc residual variance.
Individual patient data were also analyzed by subgroup of patients
either using or not using antihypertensive therapy at randomization
by adding a treatment*antihypertensive drug interaction. Analyses of
mean arterial pressure (MAP) and pulse pressure (PP) were
conducted as per the method used for changes in SBP and pulse,
except the baseline and endpoint values were log-transformed.
A Pearson correlation coefﬁcient for the potential relationship
between weight loss and reduction in SBP for liraglutide-treated
patients was also calculated. Inferential statistical tests were
performed using a 2-sided test, and statistical signiﬁcance was
deﬁned as P b 0.05. Change-from-baseline values are presented as
least squares mean change ± standard error of mean (SEM).
Statistical analyses were performed using SAS 9.3 (SAS Institute Inc.,
Cary, NC, USA).
3. Results
3.1. Demographics and baseline characteristics
Pooled patient demographics and baseline characteristics from
individuals randomized in LEAD-1–6 (n = 2792; n = 898 receiving
liraglutide 1.2 mg, n = 1366 receiving liraglutide 1.8 mg, and n =
528 receiving placebo) are presented in Table 1. Demographics and
baseline characteristics were well matched between the liraglutide
and placebo groups, perhaps with the exception of diabetes duration.
Of note, mean baseline SBP was 133 mmHg in the liraglutide 1.2 mg
group, 134 mmHg in the liraglutide 1.8 mg group, and 135 mmHg in
the placebo group.Table 1
Demographics and baseline characteristics. Randomization ratios for each of the
LEAD studies: LEAD-1 — 2:2:2:1:2 (0.6 mg liraglutide + glimepiride, 1.2 mg liraglu-
tide + glimepiride, 1.8 mg liraglutide + glimepiride, glimepiride monotherapy, gli-
mepiride + rosiglitazone); LEAD-2 — 2:2:2:1:2 (0.6 mg liraglutide + metformin,
1.2 mg liraglutide + metformin, 1.8 mg liraglutide + metformin, metformin mono-
therapy, metformin + glimepiride); LEAD-3 — 1:1:1 (1.2 mg liraglutide, 1.8 mg
liraglutide, glimepiride); LEAD-4 — 1:1:1 (1.2 mg liraglutide + rosiglitazone + met-
formin, 1.8 mg liraglutide + rosiglitazone + metformin, rosiglitazone + metformin);
LEAD-5 — 2:1:2 (1.8 mg liraglutide + glimepiride + metformin, glimepiride + met-
formin, glargine + glimepiride + metformin); LEAD-6 — 1:1 (1.8 mg liraglutide +
metformin/sulfonylurea, exenatide + metformin/sulfonylurea). HbA1c, glycosylated
hemoglobin; FPG, fasting plasma glucose.
Liraglutide 1.2 mg Liraglutide 1.8 mg Placebo
Patients randomized 898 1366 528
Male/female 450/448 720/646 291/237
Age (years) 56 56 56
BMI (kg/m2) 32 32 32
Duration of diabetes (years) 7 8 9
Body weight (kg) 89 90 91
HbA1c (%) 8.3 8.4 8.4
FPG (mmol/L) 9.8 9.7 9.8
Blood pressure (mmHg)
Systolic 133 134 135
Diastolic 80 81 813.2. Changes in systolic blood pressure (SBP)
In pooled analyses, mean SBP reductions after 26 weeks
were signiﬁcantly greater with liraglutide 1.2 mg (2.7 [0.8] mmHg)
and 1.8 mg (2.9 [0.7] mmHg) than with placebo (0.5 [0.9] mmHg);
P = 0.0029 and P = 0.0004, respectively (Fig. 1). SBP reductions
were also signiﬁcantly greater with liraglutide than with the active
comparators that were evaluated, except when comparing exenatide
with liraglutide 1.8 mg (1.2 mg dose not evaluated) and liraglutide
1.2 mg with rosiglitazone (Fig. 1).
Rapid reductions in SBP with liraglutide were evident, which were
sustained over 26 weeks (Fig. 2). Within 2 weeks, SBP had decreased
by 2.6 and 3.3 mmHg with liraglutide 1.2 and 1.8 mg, respectively,
compared with a reduction of 1.4 mmHg with placebo (Fig. 2).
3.3. Relationship between SBP reductions and weight loss
Consistent with the established effects of GLP-1 receptor agonists,
liraglutide 1.2 mg and 1.8 mg were associated with mean weight
losses of 1.2 kg and 1.8 kg, respectively, after 26 weeks (versus a
mean reduction of 0.5 kg with placebo). There was a weak, although
statistically signiﬁcant, correlation between weight loss and SBP
changes in liraglutide-treated patients at 2 and 26 weeks, and in
placebo-treated patients at 26 weeks (Table 2).
3.4. Relationship between SBP reductions and antihypertensive therapy
At randomization, 63.6% and 65.4% of the populations receiving
liraglutide 1.2 and 1.8 mg, respectively, were receiving concomitant
antihypertensive medication. Similarly, 68.8% of patients in the
placebo intention-to-treat group were receiving concomitant antihy-
pertensive medication. Very few patients (≤3%) initiated or discon-
tinued antihypertensive therapy over the 26–28-week period of
interest.
Reductions in SBP with liraglutide appeared to be independent of
concomitant antihypertensive medications: no dependence of the
observed SBP reductions with liraglutide on concomitant antihyper-
tensive medications was detected (P = 0.1304; test for treatmen-
t*antihypertensive drug interaction). The estimated treatment
differences between liraglutide (1.2 and 1.8 mg) and placebo were
similar in those who were receiving concomitant antihypertensive
medication to control BP, and those who were not (Table 3), although
placebo-adjusted SBP reductions did not reach signiﬁcance in the
latter group, possibly due to insufﬁcient statistical power.
3.5. Change in pulse
At Week 26, patients injecting liraglutide 1.2 mg or 1.8 mg had
pulse elevations of 3.22 ± 0.45 bpm and 3.46 ± 0.39 bpm (both
P b 0.0001 versus baseline), while mean pulse had increased by
0.89 ± 0.50 bpm in those receiving placebo (P = 0.08 versus
baseline). The corresponding placebo-adjusted changes with liraglu-
tide 1.2 mg and 1.8 mg were 2.33 ± 0.49 bpm and 2.57 ± 0.45 bpm,
respectively (both P b 0.0001).
No correlation was observed between change in SBP and change in
pulse in patients receiving liraglutide 1.2 mg and 1.8 mg (Pearson’s
correlation coefﬁcient at Week 26: 0.045 [P = 0.1856] and 0.003
[P = 0.9152], respectively), and placebo (0.055 [P = 0.2079]).
3.6. Changes in mean arterial pressure (MAP) and pulse pressure (PP)
While liraglutide 1.2 mg and 1.8 mg reduced MAP from baseline
after 26 weeks of treatment (−1.56 mmHg and −1.41 mmHg,
respectively; P = 0.0077 and P = 0.0091), the corresponding placebo-
adjusted changes were not statistically signiﬁcant (−0.95 mmHg
and−0.80 mmHg, respectively; P = 0.0561 and P = 0.0823). With
–8 –6 –4 –2 0 2
LS mean difference in change in SBP (mmHg)  
Liraglutide 1.8 mg vs. rosiglitazone
Liraglutide 1.2 mg vs. rosiglitazone
Liraglutide 1.2 mg vs. placebo
Liraglutide 1.8 mg vs. exenatide
Liraglutide 1.8 mg vs. insulin glargine
Liraglutide 1.8 mg vs. glimepiride
Liraglutide 1.2 mg vs. glimepiride
Liraglutide 1.8 mg vs. placebo
Fig. 1. Change in systolic blood pressure (SBP) with liraglutide versus placebo and active comparators. Diamonds indicate liraglutide–placebo or liraglutide–active comparator
estimated treatment differences in change in SBP from baseline (analysis of covariance models) for pooled data from LEAD-1–6. The width of the horizontal lines indicates 95%
conﬁdence intervals for each estimated treatment difference. LS, least squares; SBP, systolic blood pressure.
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observed with liraglutide than with glimepiride (vs. liraglutide
1.2 mg, P = 0.071; vs. liraglutide 1.8 mg, P = 0.0154) and insulin
glargine (vs. liraglutide 1.8 mg, P = 0.0154), but not with rosiglita-
zone or exenatide.
In terms of PP, signiﬁcantly greater reductions from baseline were
observed with liraglutide 1.2 mg and 1.8 mg compared with placebo
(placebo-adjusted decreases of 3.31 mmHg and 4.51 mmHg, respec-
tively; P = 0.0049 and P b 0.0001). Moreover, both liraglutide doses
resulted in signiﬁcantly greater reductions in PP compared with all
active treatments (P ≤ 0.0072) with the exception of liraglutide
1.8 mg vs. exenatide.
4. Discussion
In this patient-level pooled analysis, the administration of
liraglutide (1.2 or 1.8 mg subcutaneously, once daily) was associated
with signiﬁcantly greater reductions in SBP from baseline to 26weeks,
compared with placebo. Liraglutide was also associated with
signiﬁcantly greater SBP reductions than glimepiride and, at a dose
of 1.8 mg, insulin glargine and rosiglitazone. There were signiﬁcant
reductions in MAP with liraglutide compared with glimepiride and
insulin glargine (but not placebo, rosiglitazone or exenatide),
accompanied by a signiﬁcant fall in PP (compared with placebo and
all active comparators, with the exception of exenatide). These results126
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Fig. 2. Change in systolic blood pressure (SBP) over time. Data are last observation carried
95% conﬁdence interval.add to the pool of knowledge obtained from the individual LEAD trials,
which showed reductions in SBP of 2.1–6.7 mmHg, although with
insufﬁcient power to fully establish the effect of liraglutide on SBP
(Buse et al., 2009; Garber et al., 2009; Marre et al., 2009; Nauck et al.,
2009; Russell-Jones et al., 2009; Zinman et al., 2009).
The reductions in SBP were observed within 2 weeks of initiating
treatment with liraglutide, in agreement with a previous study of the
onset of the effects of liraglutide (Gallwitz, Vaag, Falahati, & Madsbad,
2010), which showed that the addition of liraglutide to OADs led to
rapid improvements in SBP versus placebo. Exenatide has a similar
effect on SBP (Okerson, Yan, Stonehouse, & Brodows, 2010), and
lixisenatide was also associated with small BP reductions in phase 3
clinical trials (Lyxumia (Lixisenatide) (Lixisenatide), 2013), suggest-
ing that the SBP-lowering effect may be a drug class phenomenon.
Indeed, two recent meta-analyses independently reported SBP
reductions of 1–5 mmHg with liraglutide and exenatide (Robinson,
Holt, Rees, Randeva, & O'Hare, 2013; Wang, Zhong, Lin, et al., 2013).
Here, we utilized individual patient data to investigate factors
affecting reductions in SBP with liraglutide, including weight.
The SBP reductions observed in liraglutide-treated patients
correlated weakly with weight loss, suggesting that SBP reductions
with liraglutide are mediated at least in part by a mechanism
involving weight loss. There was no correlation between change in
HbA1c with liraglutide treatment and SBP (Data on ﬁle), indicating a
mechanism independent of mid- to long-term glycemic control. Other14 16 18 20 22 24 26
eeks
Liraglutide 1.2 mg
Liraglutide 1.8 mg
Placebo
forward for the intention-to-treat population, and expressed as least squares means ±
Table 2
Pearson’s correlation coefﬁcient showing relationship between decreases in systolic blood pressure (SBP) and body weight. Data are last observation carried forward for the
intention-to-treat population.
Treatment Week Least squares means of
change in SBP (mmHg)
Least squares means of
change in body weight (kg)
Pearson’s correlation between change
in SBP and change in body weight
P value of Pearson’s correlation between
change in SBP and change in body weight
Liraglutide 1.2 mg 2 −3.11 −0.94 0.0823 0.0148
26 −2.67 −1.19 0.0920 0.0063
Liraglutide 1.8 mg 2 −2.97 −0.96 0.1084 0.0001
26 −2.91 −1.78 0.1208 b0.0001
Placebo 2 −0.63 −0.19 0.0428 0.3305
26 −0.53 −0.52 0.0923 0.0355
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lowering effects of GLP-1 receptor agonists, including GLP-1 receptor-
mediated increases in renal Na+ excretion and vasodilatation (Basu
et al., 2007; Gutzwiller, Tschopp, Bock, et al., 2004; Kim et al., 2013).
Most recently, a preclinical study linked GLP-1 receptor activation by
liraglutide to the release of atrial natriuretic peptide (ANP; well-
established as a physiological regulator of vasodilation, natriuresis
and diuresis) and BP reduction in mice, via a cAMP/Epac2-dependent
pathway (Kim et al., 2013). Two clinical studies are currently ongoing/
in recruitment to further investigate the time course and mechanisms
of the SBP reductions observed with liraglutide (Blood Pressure
Outcomes with Liraglutide Therapy [BOLT], NCT01755572; Time
Course of the Blood Pressure Lowering Effect of Liraglutide Therapy
in Type 2 Diabetes [Liratime], NCT01499108) (Mount Sinai Hospital,
2013; Rossing, 2013).
Clinicians monitoring patients in the LEAD trials had unrestricted
use and dosing of concomitant antihypertensive medications, as
hypertension was not the primary outcome of these studies. We
addressed this possible limitation and utilized this information, by
examining the effects of liraglutide in the presence and absence of
concomitant antihypertensive medications. No signiﬁcant depen-
dence of these reductions on concomitant antihypertensive medi-
cations was detected (P = 0.1304). Interestingly, the SBP reductions
associated with liraglutide were observed in both the presence and
absence of concomitant antihypertensive medication (with sufﬁ-
cient statistical power to detect signiﬁcance versus placebo in the
group receiving antihypertensive medications). Thus, the effects of
liraglutide and concomitant antihypertensive medications on SBP
appear to be additive, which is likely to be a welcome outcome in
the many patients who have type 2 diabetes complicated by
hypertension. Prior studies have demonstrated clinical beneﬁts from
SBP reductions in hypertensive patients with type 2 diabetes (Adler
et al., 2000; Kearney et al., 2008; UK Prospective Diabetes Study
Group, 1998).
The clinical consequences of the dose-independent increase in
pulse of 3 bpm noted with liraglutide are unclear. The exact
mechanisms underlying this increase are also yet to be elucidated.Table 3
Changes in systolic blood pressure (SBP) with liraglutide versus placebo at the end of 26
carried forward for the intention-to-treat population.
n
Patients receiving concomitant antihypertensive medications
Treatment Liraglutide 1.2 mg 560
Liraglutide 1.8 mg 884
Placebo 358
Estimated treatment differences Liraglutide 1.2 mg − Placebo
Liraglutide 1.8 mg − Placebo
Patients not receiving concomitant antihypertensive medications
Treatment Liraglutide 1.2 mg 320
Liraglutide 1.8 mg 467
Placebo 162
Estimated treatment differences Liraglutide 1.2 mg − Placebo
Liraglutide 1.8 mg − PlaceboAlthough a compensatory increase in heart rate in response to the
decrease in BP has been suggested, there was no correlation between
change in SBP and change in pulse. A resting heart rate elevation in
excess of 10 bpm has been positively correlated with CV and all-cause
mortality (Jensen, Marott, Allin, Nordestgaard, & Jensen, 2012), hence
caution is warranted for drugs that substantially increase heart rate.
The mean increases in pulse observed with GLP-1 receptor agonists
reported here and elsewhere (Robinson et al., 2013) were below
4 bpm. Furthermore, themajor adverse CV events (MACE) analysis for
liraglutide conducted as part of the Food and Drug Administration
(FDA) regulatory review did not indicate any increase in CV risk with
liraglutide (Marso, Lindsey, Stolker, et al., 2011).
The long-term CV safety of liraglutide is being prospectively
studied in 9340 patients with type 2 diabetes and a high CV risk
proﬁle in the ‘Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results — A Long Term Evaluation’ (LEADER;
NCT01179048) trial (Bergenstal, Daniels, Mann, et al., 2011; Novo
Nordisk, 2013a). This study will provide valuable insights as to
whether reductions in SBP with liraglutide therapy (coupled with
improvements in other risk factors, such as body weight and glucose
control) might translate into a beneﬁcial effect on CV morbidity and
mortality. Long-term outcome trials are also ongoing for the GLP-1
receptor agonists exenatide (Exenatide Study of Cardiovascular Event
Lowering Trial [EXSCEL]: NCT01144338) (Amylin Pharmaceuticals,
LLC, 2012), lixisenatide (Evaluation of Cardiovascular Outcomes in
PatientsWith Type 2 Diabetes After Acute Coronary Syndrome During
Treatment With AVE0010 (Lixisenatide) [ELIXA]: NCT01147250)
(Sanoﬁ, 2013), dulaglutide (Researching Cardiovascular Events With
aWeekly Incretin in Diabetes [REWIND]: NCT01394952) (Eli Lilly and
Company, 2013) and semaglutide (SUSTAIN 6; NCT01720446) (Novo
Nordisk, 2013b).
In conclusion, this patient-level pooled analysis showed that, in
patients with type 2 diabetes, liraglutide 1.2 and 1.8 mg produced
statistically signiﬁcant SBP reductions that were evident within
2 weeks and sustained to 26 weeks. The reductions in SBP were
weakly correlated with weight loss and observed in the presence and
absence of antihypertensive therapy. Together, these ﬁndings raiseweeks by concomitant antihypertensive medication status. Data are last observation
Least squares mean change (mmHg) Standard error P value
−1.44 0.87 0.0989
−2.02 0.78 0.0105
+0.61 0.95 0.5187
−2.05 0.86 0.0171
−2.63 0.80 0.0010
−4.42 0.97 b0.0001
−4.06 0.86 b0.0001
−2.21 1.18 0.0612
−2.21 1.21 0.0680
−1.85 1.15 0.1058
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